poudre pour inhalation

DRUG4 trials

Sponsors

Hospices Civils De Lyon, Glaxosmithkline Research & Development Limited

Conditions

AsthmaChronic Obstructive Pulmonary Disease

Phase 3

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation

RecruitingCTIS2024-520417-41-00

Glaxosmithkline Research & Development LimitedChronic Obstructive Pulmonary Disease

Start: 2026-01-07Target: 327Updated: 2026-01-20

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.

RecruitingCTIS2024-520418-22-00

Glaxosmithkline Research & Development LimitedChronic Obstructive Pulmonary Disease

Start: 2026-01-20Target: 453Updated: 2026-01-09

A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.

Not yet recruitingCTIS2025-521108-23-00

Glaxosmithkline Research & Development LimitedChronic Obstructive Pulmonary Disease

Target: 165Updated: 2026-04-08

Phase 4

Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE

CompletedCTIS2022-501029-19-00

Hospices Civils De LyonAsthma

Start: 2022-12-13End: 2025-03-27Target: 130Updated: 2024-01-15